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Background: Mental health problems are common and are associated with increased disability and health care
costs. Problem-Solving Treatment (PST) delivered to these patients by nurses in primary care might be efficient. The
aim of this study was to evaluate the cost-effectiveness of PST by mental health nurses compared with usual care
(UC) by the general practitioner for primary care patients with mental health problems.
Methods: An economic evaluation from a societal perspective was performed alongside a randomized clinical trial.
Patients with a positive General Health Questionnaire score (score ≥ 4) and who visited their general practitioner at
least three times during the past 6 months were eligible. Outcome measures were improvement on the Hospital
Anxiety and Depression Scale and QALYs based on the EQ-5D. Resource use was measured using a validated
questionnaire. Missing cost and effect data were imputed using multiple imputation techniques. Bootstrapping was
used to analyze costs and cost-effectiveness of PST compared with UC.
Results: There were no statistically significant differences in clinical outcomes at 9 months. Mean total costs were
€4795 in the PST group and €6857 in the UC group. Costs were not statistically significantly different between the
two groups (95% CI -4698;359). The cost-effectiveness analysis showed that PST was cost-effective in comparison
with UC. Sensitivity analyses confirmed these findings.
Conclusions: PST delivered by nurses seems cost-effective in comparison with UC. However, these results should
be interpreted with caution, since the difference in total costs was mainly caused by 3 outliers with extremely high
indirect costs in the UC group.
Trial registration: Nederlands Trial Register ISRCTN51021015
Keywords: Costs and cost analysis, Problem-solving treatment, Nurses, Depression, Anxiety, Primary health careBackground
Mental health problems are prevalent, with depression
and anxiety being most common [1-3]. The disability
burden of mental health problems is enormous [3].
Moreover, mental health problems are associated with
high health care costs and lost productivity costs, thus
causing a huge economic burden as well [4-6].* Correspondence: j.e.bosmans@vu.nl
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reproduction in any medium, provided the orMost patients with mental health problems receive
primary care [7]. The perceived burden on general prac-
titioners (GPs) when treating these patients is higher
than when treating other patients [8]. Treatment mainly
consists of psychotropic drugs [7,9], although these
drugs have disadvantages such as side effects, depend-
ency and poor compliance. Moreover, many patients
prefer psychological treatments over psychotropic drugs
and advice [10,11]. However, most GPs have little experi-
ence in delivering psychological interventions and there
is little evidence on the effectiveness of psychologicalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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questionable whether busy GPs have time to provide
psychological treatment to patients with mental health
problems. Psychological treatments could be made more
widely available, if other health care providers could pro-
vide these treatments in an integrated primary care
setting.
Problem-Solving Treatment (PST) is a psychological
treatment that has been shown to be effective for de-
pression in primary care and that can be effectively
delivered by nurses or GPs [13,14]. However, for unse-
lected patients with mental health problems who con-
stitute the bulk of the primary care caseload, evidence
of the effectiveness of PST was less clear and PST was
associated with significantly higher health care costs
than usual GP care [15,16]. The aim of this study was
to assess the cost-effectiveness of PST by mental
health nurses compared with usual GP care for pri-
mary care patients with mental health problems in
The Netherlands.
Methods
This economic evaluation was conducted alongside a
randomized controlled trial with nine month follow-up
that was performed in 12 general practices in and
around Amsterdam, The Netherlands, between Novem-
ber 2003 and May 2005. The Medical Ethical Commit-
tee of the University Medical Center in Amsterdam
approved the study protocol. Block randomization was
used to allocate patients to either PST provided by a
mental health care nurse or usual care from the GP.
All patients gave written informed consent before
randomization. The methodological details of the trial
and the three months effectiveness results are reported
in detail elsewhere [17,18].
Patient selection
Consecutive patients who visited their GP were invited
to complete the General Health Questionnaire (GHQ-
12) [19]. Patients were eligible for the trial if they had a
score of 4 points or more on the GHQ-12 [15,20], and
visited their GP three times or more in the previous six
months. Patients had to be 18 years or older, able to
speak Dutch, and willing to undergo brief psychological
treatment. Exclusion criteria were the existence of po-
tentially life-threatening somatic and mental disorders,
the existence of somatic and mental disorders limiting
the patient’s ability to participate or adhere to treatment,
and mental health treatment during the previous year.
Usual care
Treatment of mental health problems in the usual care
(UC) group was not restricted in any way. Dutch GPs
are encouraged to work according to guidelines issuedby the Dutch College of GPs [21,22]. The depression
guidelines recommend that treatment of depression pri-
marily consists of education and coaching. Antidepres-
sant treatment and/or referral for psychotherapy can be
added, depending on the duration and severity of the de-
pressive symptoms, the limitations in daily functioning,
and the patient’s preference [22]. For anxiety, the guide-
lines recommend referral for psychotherapy and medica-
tion if indicated [21].
PST
PST is a brief treatment focused on practical skill build-
ing, education, and managing depressive symptoms.
The goal is to stimulate an active attitude towards
everyday problems and, hereby, to achieve a reduction
in mental health problems. Twelve nurses working at
one of the mental healthcare organizations in Amster-
dam were trained during two days by two researchers
who developed PST for primary care, L. Mynors-Wallis
and I. Davies. In the second part of the training, the
nurses treated four patients closely supervised by a cog-
nitive behavioral therapist (PvO). The supervisor was
certified as supervisor by the National Association of
Behavior Therapy and Cognitive Therapy in The
Netherlands.
Patients were offered four to six PST sessions. The first
session lasted a maximum of 60 minutes and following
sessions a maximum of 30 minutes. Patients could visit
their GP for UC if necessary.
Clinical outcome measures
The participants received written questionnaires at base-
line, and at three and nine months after baseline. The
primary clinical outcome was severity of mental health
symptoms measured using the Hospital Anxiety and De-
pression Scale (HADS) [23]. Lower scores on the HADS
indicate less severe symptoms. Quality of life was mea-
sured using the EQ-5D [24]. The EQ-5D scores were
used to calculate utilities using the Dutch tariff [25].
QALYs were calculated using linear interpolation be-
tween time points. Higher QALY scores indicate more
improvement in quality of life.
Cost measures
Cost data were collected from a societal perspective 3
times during the 9 months follow-up using the TiC-P
questionnaire with a recall period of 3 months [26]. If
available, Dutch guideline prices were used to value re-
source use [27,28]. Medication was valued using prices
of the Royal Dutch Society for Pharmacy [29]. Costs of
visits to complementary therapists were based on prices
from the therapists themselves. Lost productivity costs
were calculated according to the friction cost approach
(friction period 154 days) using the mean age- and sex-
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to the friction cost approach a sick employee is replaced
after a certain amount of time (the friction period) after
which there are no lost productivity costs anymore.
Table 1 lists the cost categories included in the eco-
nomic evaluation and the prices used. All costs were
adjusted to the year 2012 using consumer price indices
[30].
Analysis
It was estimated that 65 patients in each group would be
needed to detect an effect size of 0.4 (2-sided α=0.05,
β=0.20). Taking into account a drop-out rate of 20%, the
aim was to include 160 patients into the trial.
The statistical analyses were performed according to
the intention-to-treat principle. Multiple Imputation
(MI) according to the Multivariate Imputation by
Chained Equations (MICE) algorithm was done to im-
pute missing cost and effect data with SPSS 17.0 for
Windows (SPSS Inc., Chicago, IL, USA). Predictive mean
matching was used to account for the skewness of the
cost data and the fact that costs are bounded by zero.
An imputation model was constructed that included
variables that were related to missingness or predictedTable 1 Health care utilization over 9 months of patients with
Category Price (€)
Primary care
General practitioner [no contacts] 23.53
Physiotherapist [no contacts] 26.50
Social worker [no contacts] 55.75
Psychologist [no contacts] 88.53
Secondary care
Outpatient clinic [no contacts] 65.23
Regional institute for mental welfare [no contacts] 144.44
In-hospital psychiatrist [no contacts] 73.88 – 131.94
Day treatment [no half days] 104.28 – 186.21
Hospital admission [no days] 291.21 – 554.45
Home care [no hours] 35.76
Complementary therapists [no contacts] 26.79 – 143.28
Occupational physician [no contacts] 24.75
Medication [no deliveries] depending on type a
PST [no contacts] 56.87}
Help from family/friends or paid help [no hours] 10.36
Absenteeism [no days] depending on age an
Presenteeism [no days] depending on age an
Presented are means (SD) and mean differences (95% CI).
PST = Problem-Solving Treatment.
* depending on type of hospital: academic, general or psychiatric hospital.
† depending on type of hospital: academic, general, rehabilitation or psychiatric ho
{ depending on type of therapist.
} Total PST costs based on 6 sessions: €341.24 (training €45.08, treatment €244.24, hthe outcome variable. By MI 5 imputed data sets were
created, each of which was analyzed separately. The
results of the 5 analyses were pooled using Rubin’s rules
[31].
Linear regression was used to estimate differences in
costs and effects. Costs generally have a highly skewed
distribution. Therefore, bootstrapping with 5000 repli-
cations was used to estimate “approximate bootstrap
confidence” (ABC) intervals around cost differences
[32,33].
Incremental cost-effectiveness ratios (ICERs) were cal-
culated by dividing the difference in total costs between
PST and UC by the difference in clinical effects. Non-
parametric bootstrapping was also used to estimate
the uncertainty surrounding the incremental cost-
effectiveness and cost-utility ratios (5000 replications).
The bootstrapped cost-effect pairs were plotted on a
cost-effectiveness plane [34] and used to estimate cost-
effectiveness acceptability curves. Cost-effectiveness
acceptability curves show the probability that the inter-
vention is cost-effective in comparison with the control
treatment for a range of ceiling ratios. The ceiling ratio is
defined as the amount of money society is willing to pay
to gain one unit of effect [35].complete cost data
PST (n=56) Usual care (n=65) Difference
4.1 (3.3) 4.8 (4.5) −0.7 (−2.1 ; 0.8)
5.5 (10.3) 6.0 (11.0) −0.5 (−4.4 ; 3.4)
0.3 (1.9) 0.2 (0.8) 0.1 (−0.5 ; 0.5)
1.1 (5.0) 1.0 (2.7) 0.1 (−1.3 ; 1.6)
2.3 (3.4) 4.2 (10.2) −1.9 (−4.6 ; 0.8)
0.3 (0.9) 0.5 (1.9) −0.2 (−0.8 ; 0.3)
* 0.1 (0.7) 0.2 (0.9) −0.1 (−0.4 ; 0.2)
* 0 (0) 0 (0) –
† 0.3 (1.1) 1.3 (5.8) −1.0 (−2.4 ; 0.5)
4.2 (16.0) 7.9 (29.4) −3.7 (−12.4 ; 5.0)
{ 1.4 (3.8) 1.8 (4.8) −0.4 (−1.9 ; 1.2)
0.4 (1.4) 0.8 (1.6) −0.4 (−0.9 ; 0.2)
nd dose 7.0 (6.8) 7.4 (6.5) −0.4 (−2.8 ; 2.0)
4.1 (2.1) –
14.9 (32.8) 12.5 (34.2) 2.4 (−9.8 ; 14.5)
d sexe 19.5 (54.8) 29.0 (62.4) −9.5 (−30.8 ; 11.8)
d sexe 3.8 (12.9) 7.2 (19.9) −3.4 (−10.0 ; 2.7)
spital.
ousing €51.92).
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Six sensitivity analyses were performed to assess the ro-
bustness of the results. In the first sensitivity analysis,
statistical analysis was restricted to patients with
complete follow-up data. Secondly, we redid the eco-
nomic evaluation from a NHS perspective meaning that
only direct costs were included in the analyses. In the
third sensitivity analysis, lost productivity costs were cal-
culated according to the human capital approach. This
approach assumes that lost productivity costs are gener-
ated until an employee recovers and returns to work, or
until the moment of death or retirement. In the fourth
sensitivity analysis, training costs were excluded from
the PST intervention costs. The fifth sensitivity analysis
concerned a per protocol analysis in which only PST
patients were included who completed 4 or more PST
sessions. Finally, in the sixth sensitivity analysis the
observed outliers with very high lost productivity costs
were excluded from the analysis.
Results
During the inclusion period, 2133 patients completed
the GHQ-12 and 353 refused to participate. 622 patients
had a score of 4 or more on the GHQ-12 and visited
their GP three times or more in the past 6 months. 311
patients were unwilling to participate in the trial and
136 did not meet the inclusion criteria, leaving 175
patients to be included in the trial of whom 88 were ran-
domized to the PST group and 87 to the UC group.
At baseline, utility was significantly lower in UC
patients than in PST patients meaning that the health
status of UC patients was lower than of PST patients.
All analyses concerning QALYs were corrected for this
baseline difference. There were no other significant dif-
ferences in clinical and demographic characteristics be-
tween the treatment groups at baseline (Table 2).Table 2 Baseline characteristics
PST (n=88) Usual care (n=87)
Mean (SD) age (years) 52 (16) 53 (16)
Female 68 (77%) 57 (66%)
Married/cohabiting 34 (39%) 33 (38%)
Education level
Low 17 (19%) 14 (16%)
Medium 22 (25%) 23 (26%)
High 31 (35%) 32 (37%)
Unknown 18 (21%) 18 (21%)
Born in The Netherlands 62 (71%) 60 (69%)
Mean EuroQol utility (SD) 0.73 (0.18) 0.62 (0.28)
Mean HADS score (SD) 15.4 (7.5) 16.9 (7.1)
Presented are numbers (%) unless stated otherwise.
HADS = Hospital Anxiety Depression Scale.Complete cost data were available for 56 (64%) of the
PST patients and 65 (75%) of the UC patients. There
were no significant differences in baseline characteristics
between patients with and without complete cost data.
Clinical effects
Clinical effects are presented in Table 3. After 9 months
the multiply imputed pooled improvement in HADS
score was −3.1 (SE 1.3) in PST patients and −2.9 (SE
1.0) in UC patients indicating that PST patients
improved more than UC patients. However, this differ-
ence was not statistically significant (mean difference −0.2,
95% CI −3.7; 3.2).
The mean pooled utility score based on the Dutch tariff
for the EQ-5D was 0.71 in the PST group and 0.61 in the
UC group. After 3 and 9 months the pooled utility scores
were 0.76 and 0.73, respectively, in the PST group and 0.66
and 0.70, respectively, in the UC group. The mean number
of QALYs after 9 months was 0.56 (SE 0.02) in the PST
group and 0.50 (SE 0.02) in the UC group. After correction
for baseline utility, the difference in QALYs between PST
and UC was in favour of the PST group (0.03), but statisti-
cally non-significant (95% CI −0.02; 0.08).
Health care utilization
Table 1 presents the health care utilization in the PST
and the UC groups at 9 months for patients with
complete cost data. In general, health care utilization in
the PST group was slightly lower than in the UC group
for both general and mental health care.HADS −3.1 (1.3) −2.9 (1.0) −0.2 (−3.7 ; 3.2)
QALY 0.56 (0.02) 0.49 (0.02) 0.03 (−0.02 ; 0.08)*
Cost category
Direct costs 1751 (221) 2004 (340) −253 (−1149 ; 476)
Direct healthcare
costs
1362 (202) 1829 (326) −467 (−1340 ; 202)
Direct non-healthcare
costs
214 (46) 175 (56) 40 (−117 ; 166)
PST costs 174 (15) 0 (0) 174 (143 ; 206)
Indirect costs 3768 (703) 5889 (1187) −2121 (−4788 ; 396)
Costs absenteeism 2991 (708) 4319 (951) −1328 (−3748 ; 823)
Costs presenteeism 778 (251) 1570 (581) −792 (−2343 ; 209)
Total costs 4795 (671) 6857 (1128) −2062 (−4698 ; 359)
Presented are means (SEs) and mean differences (95% CIs).
PST = Problem-Solving Treatment; HADS = Hospital Anxiety Depression Scale;
QALY = Quality-Adjusted Life-Years.
* corrected for baseline utility.
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session. On average, PST patients received 3 PST ses-
sions. During the study period, 51 (91%) PST patients
and 57 (88%) UC patients visited the general practitioner
at least once. Thirty-two (36%) PST patients received
some form of mental health care (referral to a mental
health care provider or prescription of either an anti-
depressant or benzodiazepine) in comparison with 33
(38%) UC patients during follow-up. Absenteeism in the
UC group was substantially higher than in the PST
group. There were 2 (4%) patients in the PST group and
4 (6%) patients in the UC group who were absent for
more than 180 days.
Costs
Table 3 presents the imputed pooled mean total costs in
the PST and UC group after 9 months. Both direct and
indirect costs in the PST group were lower than in the
UC group. Indirect costs were the greatest contributor
to mean total costs. Mean PST costs amounted to €174
(SE 15). Mean total costs in the PST group were €2062
lower than in the UC group, but this difference was not
statistically significant (95% CI -4698; 359).
Total mental health care costs were €485 in the PST
group and €259 in the UC group. Although this differ-
ence was considerable, it did not reach statistical signifi-
cance (mean difference €226, 95% CI -3; 448).
Cost-effectiveness
The results of the cost-effectiveness and cost-utility
analyses are presented in Table 4. The ICER forTable 4 Results of cost-effectiveness and cost-utility analyses
Analysis Sample size Outcome Cost differen
PST UC (95% C
Multiply imputed analysis 88 87 HADS −2062 (−4698
88 87 QALY* −2062 (−4698
Complete cases 56 63 HADS −2715 (−5858
53 59 QALY* −3085 (−6300
NHS perspective† 88 87 HADS −253 (−1149
88 87 QALY* −253 (−1149
Human capital approach 88 87 HADS −2397 (−5427
88 87 QALY* −2397 (−5427
Training costs PST excluded 88 87 HADS −2035 (5669 ;
88 87 QALY* −2035 (5669 ;
Per protocol analysis 41 87 HADS −3220 (−5744
41 87 QALY* −3220 (−5744
Observed outliers excluded 88 84 HADS −1090 (−3492
88 84 QALY* −1090 (−3492
HADS = Hospital Anxiety and Depression Scale; QALY = Quality-Adjusted Life-Year;
* adjusted for baseline utility score.
† only direct costs included.improvement in total HADS score at 9 months was
8676, meaning that one point improvement extra in
the PST group costs €8676 extra in comparison with
the UC group. In the CE plane, only 5% of the cost-
effect pairs was located in the NE and NW quadrants,
while 55% and 40% of the cost-effect pairs was located
in the SE and SW quadrant, respectively. The cost-
effectiveness acceptability curve in Figure 1 shows that
for a ceiling ratio of €0 per point of improvement on
the HADS, the probability that PST is cost-effective in
comparison with UC is 0.95. For higher ceiling ratios
this probability decreases slowly to 0.57.
The difference in QALYs after 9 months between the
PST and UC groups was very small leading to a very
large ICER. The CE plane showed that 88% and 7% of
the cost-effect pairs was located in the SE and SW quad-
rants, respectively. The cost-effectiveness acceptability
curve in Figure 2 shows that PST is considered cost-
effective in comparison with UC for all ceiling ratios.
Sensitivity analyses
Results of the sensitivity analyses are presented in
Table 4. PST was considered cost-effective in compari-
son with UC in all sensitivity analyses. In the complete
case analyses, differences in clinical effects were small
and not statistically significant. Total costs in the PST
group were significantly lower than in the UC group.
Therefore, PST was considered cost-effective in com-
parison with UC in the complete case analyses.
In the sensitivity analysis performed from the NHS
perspective, costs in the PST group were €253 lowerce (€) Effect difference ICER Distribution CE plane
I) (95%CI) NE SE SW NW
; 359) −0.2 (−3.7 ; 3.2) 8676 2% 55% 40% 3%
; 359) 0.03 (−0.02 ; 0.08) −65045 4% 88% 7% 1%
; 77) 0.02 (−2.3 ; 2.4) −113112 1% 48% 49% 2%
; -171) 0.04 (−0.01 ; 0.08) −83380 2% 94% 4% 0%
; 476) −0.2 (−3.7 ; 3.2) 1065 11% 45% 28% 16%
; 476) 0.03 (−0.02 ; 0.08) −7984 23% 69% 4% 4%
; 393) −0.2 (−3.7 ; 3.2) 10084 2% 55% 40% 3%
; 393) 0.03 (−0.02 ; 0.08) −75597 4% 88% 7% 1%
1259) −0.2 (−3.7 ; 3.2) 8564 6% 50% 38% 6%
1259) 0.03 (−0.02 ; 0.08) −64198 11% 81% 7% 1%
; -725) 1.5 (−1.5 ; 4.4) −2943 0% 16% 84% 0%
; -725) 0.03 (−0.03 ; 0.09) −137279 0% 90% 10% 0%
; 1175) −0.3 (−3.8 ; 3.3) 4297 7% 49% 33% 11%
; 1175) 0.03 (−0.02 ; 0.08) −34498 15% 77% 5% 3%




















Figure 1 Cost-effectiveness acceptability curve for
improvement in total HADS score after 9 months.
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non-significant. CEA curves suggest that the willingness
to pay should be high to consider PST cost-effective in
comparison with UC (data not shown).
Use of the human capital approach led to higher esti-
mates of indirect and total costs in both groups. How-
ever, the difference in total costs changed from -€2062
to -€2397 which was not statistically significant. In this
analysis, PST was also considered cost-effective in com-
parison with UC.
Excluding training costs from the PST costs, resulted
in lower costs for the PST treatment (€151). The differ-
ence in total costs between PST and UC in this sensitiv-
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Figure 2 Cost-effectiveness acceptability curve for QALYs after
9 months.significant (95% CI -5669; 1259). The conclusion regard-
ing cost-effectiveness did not change in this analysis.
In the per protocol analysis, the difference in total
costs was -€-3220 which was statistically significant
(95% CI -5744; -725). The differences in improvement in
HADS score and QALY were somewhat larger than in
the main analysis, but these differences were not statisti-
cally significant. PST was considered cost-effective in
comparison with UC.Discussion
Our results show that there were no significant differ-
ences in effects between PST and UC patients in this
population of primary care patients with relatively mild
levels of distress. The cost difference between PST and
UC was substantial, but not statistically significant. Cost-
effectiveness planes and acceptability curves show that
PST was cost-effective in comparison with UC. Indirect
costs in the PST group were substantially lower than in
the UC group and were the greatest contributor to the
difference in total costs. However, this difference was
mainly caused by 3 outliers in the UC group. Sensitivity
analyses confirmed the small differences in effects and
that costs in the PST group were substantially lower
than in the UC group. Based on these analyses, PST was
also considered cost-effective in comparison with UC in
this study. Analyses from the NHS perspective suggested
that PST is not considered cost-effective in comparison
with UC.
UC patients had significantly lower utility scores at
baseline than PST patients. Therefore, we suspect that
morbidity rates in the UC group were higher than in the
PST group. This may also explain the higher costs in the
UC group. Additional analyses showed that the differ-
ences in direct and indirect costs were only partially
explained by the difference in utility score at baseline
(data not shown).
One of the strengths of this trial is that it was a prag-
matic trial, meaning that we tried to resemble daily clin-
ical practice as much as possible. By applying as few
restrictions as possible on patient selection, we think we
succeeded in recruiting a population that is representa-
tive of the patients with mental health problems seen by
the GP. Also, we tried to model the GP’s normal care
process as much as possible. Therefore, the results of
this study are likely to be generalisable to the rest of The
Netherlands and other countries with similar health care
systems.
Research suggests that a considerable part of lost
productivity costs in mental disorders is caused by pres-
enteeism [36,37]. Therefore, another important strength
of this study is that both costs of absenteeism and pres-
enteeism (being present at work, but at reduced work
Bosmans et al. BMC Family Practice 2012, 13:98 Page 7 of 8
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included only costs of absenteeism [15,16].
Our study also has some limitations. First, our study
was underpowered to detect relevant cost differences
which is reflected in the wide confidence intervals
around the cost differences. This is a common problem
in economic evaluations alongside clinical trials. Because
of the heavily skewed distribution of cost data, very large
numbers of patients are needed to detect relevant cost
differences [38]. Second, the number of patients that did
not return all cost questionnaires was considerable (PST
group 36%, UC group 25%). However, there were no sig-
nificant differences between patients with and without
complete cost data, reducing the chance of bias caused
by selective drop-out. Moreover, both the results of the
imputed analysis and the complete case analysis showed
that PST is cost-effective in comparison with UC. Fi-
nally, the follow-up period of the trial may have been
too short. If PST indeed is beneficial in comparison with
usual care, then it is reasonable to assume that these
benefits extend over many years.
Our results can be compared with two other studies
that included an economic evaluation of PST for primary
care patients with mental health problems [15,16]. Our
results are consistent with their findings that PST is not
effective in comparison with usual GP care. These stud-
ies showed that PST was associated with higher costs
than usual GP care, while in our study lower costs were
found in the PST group. Possible explanations for this
discrepancy include the length of the follow-up (9
months in this study versus 6 months in the other stud-
ies), the higher costs of the PST in the other studies, and
the cost categories that were included.
The accompanying clinical trial showed in a post-hoc
analysis that a sub-group of more severely depressed
patients could benefit from PST [18]. This is in line with
earlier research [13,14]. A recent review showed that
PST is more effective in comparison with GP care for
depression, and mixed anxiety and depression [39].
Thus, it is reasonable to assume that PST should be
reserved for patients with more severe mental health
symptoms. A potential fruitful avenue is the develop-
ment of stepped care approaches in which PST is offered
to patients who do not recover or deteriorate during a
period of ‘watchful waiting’.
Conclusions
In conclusion, this study shows that PST did not result
in improved clinical outcomes in comparison with UC,
but did result in substantially lower costs which are
explained by the lower indirect costs in the PST group.
Based on these results, PST was considered cost-
effective in comparison with usual care, although not
from an NHS perspective. Since, most of the differencein costs in our study was caused by 3 outliers with very
high lost productivity costs, a too strong conclusion on
the cost-effectiveness of PST cannot be drawn based on
the results of this study.
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